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Abstract: Facioscapulohumeral muscular dystrophy (FSHD) has been associated with the genetic
and epigenetic molecular features of the CpG-rich D4Z4 repeat tandem array at 4q35. Reduced DNA
methylation of D4Z4 repeats is considered part of the FSHD mechanism and has been proposed
as a reliable marker in the FSHD diagnostic procedure. We considered the assessment of D4Z4
DNA methylation status conducted on distinct cohorts using different methodologies. On the basis
of the reported results we conclude that the percentage of DNA methylation detected at D4Z4
does not correlate with the disease status. Overall, data suggest that in the case of FSHD1, D4Z4
hypomethylation is a consequence of the chromatin structure present in the contracted allele, rather
than a proxy of its function. Besides, CpG methylation at D4Z4 DNA is reduced in patients presenting
diseases unrelated to muscle progressive wasting, like Bosma Arhinia and Microphthalmia syndrome,
a developmental disorder, as well as ICF syndrome. Consistent with these observations, the analysis
of epigenetic reprogramming at the D4Z4 locus in human embryonic and induced pluripotent stem
cells indicate that other mechanisms, independent from the repeat number, are involved in the control
of the epigenetic structure at D4Z4.
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1. Introduction
Facioscapulohumeral muscular dystrophy (FSHD, OMIM#158900) is the third most common
myopathy with a reported prevalence ranging between 1 in 8333 [1] and 1 in 20,000 [2]. FSHD is
characterized by insidious onset and progressive wasting of a highly selective set of muscle groups, the
facial, limb girdle, and foot extensor muscles, and by a great variability of clinical expression among
patients and within families [3,4]. The disease appears significantly earlier in males [5–7] and this
determines male patients to be in higher number and more severely affected than females [5,6,8–10].
In some families, individuals affected by FSHD can be found only in one generation [5,7,11,12]. These
differences are striking in discordant monozygotic twins [13–15].
Genetically, FSHD has been considered a Mendelian disease with autosomal dominant inheritance
twins [16–18]. On this basis, the FSHD genetic locus was mapped on chromosome 4q35 by genetic
linkage analysis [16,18,19] and associated with rearrangements of an array of tandemly repeated 3.3 kb
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segments (D4Z4) [20]. FSHD is the only human disease causally linked to copy number variation of
macrosatellite DNA elements [21]. The number of D4Z4 repeats varies from 11 to 100 in the general
population, whereas 10 repeats or fewer are usually found in sporadic and familial FSHD patients. As a
general rule, alleles composed by 11–100 copies of D4Z4 repeats constitute the normal size range of D4Z4
alleles, whereas alleles with 8 or fewer D4Z4 repeats are considered diagnostic for the disease [22,23].
The routine DNA molecular testing, based on the identification of D4Z4 arrays with less
than 10 units at 4q35, has been considered highly sensitive and specific [23,24]. However, several
genotype–phenotype studies have shown that D4Z4 reduction (4–8 reduced units, RU) is also present
in 3% of the general population [25–28] and in some cases is associated with distinct myopathic
phenotypes not reminiscent of FSHD [29,30]. Moreover, 10% of FSHD patients carry D4Z4 alleles
of borderline size (9–10 RU), which are also found in healthy people or in subjects with a different
myopathy [31] (Ricci et al., submitted). Finally, 5–10% of FSHD patients carry D4Z4 arrays of size
within the range of the general population (11 RU or more) on both chromosomes 4q [32,33]. These
subjects represent a second form of disease, FSHD2. Therefore, the number of D4Z4 RU at 4q35 does
not per se characterize FSHD (Figure 1).
As a matter of fact, genotype–phenotype studies have shown a large spectrum of clinical
phenotypes in myopathic subjects [29–31], carrying a D4Z4 reduced allele as well as reduced penetrance
among relatives carrying the same D4Z4 reduced allele [7,9,10,12,25,34,35]. All this has relevant effects
on clinical practice, complicating diagnosis, prognosis, and genetic counseling.
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Figure  1.  Molecular  complexity  in  facioscapulohumeral  muscular  dystrophy  (FSHD).  D4Z4 
contractions are associated with a permissive 4qA genotype that involves the aberrant expression of 
the DUX4 retrogene and is responsible for FSHD1, but also occurs in 1.3–2% of the normal population. 
4qA  is  also  found  in  cases presenting  complex  phenotypes  and  as well  as  in  30–50%  of  healthy 
relatives. Mutations  in  SMCHD1  or DNMT3B  genes  have  been  associated with  FSHD2  and  are 




The D4Z4 repeat  is part of a  family of 3.3 kb sequences  frequently  found  in heterochromatic 





Figure 1. Molecular complexity in facioscapul humeral muscular dystroph (FSHD). D4Z4 contractions
are ass ciated with a permissive 4qA genotype that involves he aberrant exp ession of the DUX4
retrogen and is respo sible fo FSHD1, but also occurs in 1.3–2% of the normal popul tion. 4qA is also
found in cases presenting complex phenotypes and as well as in 30–50% of healthy relatives. Mutations
in SMCHD1 or DNMT3B genes have been associated with FSHD2 and are responsible for ICF and
BAMS syndromes. Parents of ICF patients are heterozygous for DNMT3B pathogenic variants but do
not show any sign of muscular dystrophy. Other myopathic patients carry SMCHD1 mutations. Grey
dot = methyl CpG; white dot = unmethylated CpG.
2. Molecular Features and the Epigenetic Model for FSHD
The D4Z4 repeat is part of a family of 3.3 kb sequences frequently found in heterochromatic
regions, such as the short arms of the acrocentric chromosomes [36], and a nearly identical and equally
polymorphic D4Z4 array reside at the sub-telomere of chromosome 10q [37,38].
D4Z4 is a CpG-rich (73%) macrosatellite DNA element ncompassing more than 16 nucleosomes
and containing multiple repeat seque ces normally associated with heterochromatin [36]. The D4Z4
repeat unit contains the open reading frame of the retrogene DUX4.
Studies showed that D4Z4 plays a role in control of gene silencing at 4q35 through the recruitment
of a multi-protein repressor complex, the D4Z4 Recognition Complex (DRC), composed of YY1,
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HMGB2, and Nucleolin, binding a 27bp DNA element within the D4Z4 sequence (D4Z4 Binding
Element, DBE) [39]. The factor YY1 is a component of multiple chromatin regulatory complexes,
including the Polycomb Repressive Complex 2 (PRC2), which includes the H3K27 methyltransferase
EZH2 [40]. YY1 also interacts with histone deacetylase 1 (HDAC1), HDAC2, and HDAC3 [41], as well
as with PARP1 [42]. A long non coding RNA, DBE-T, encoded within the 4q35 locus, is selectively
transcribed in FSHD samples and participates in the transcriptional and epigenetic regulation of the
4q35 genes [43].
Several clinical features, such as penetrance variability, gender bias in severity [6], asymmetric
muscle wasting, and discordance in monozygotic twins [13–15], suggest that FSHD development
involves epigenetic factors which might influence gene expression through local modification of
chromatin structure.
Indeed, the great clinical heterogeneity and molecular uncertainty has pointed to the need for additional
markers to support FSHD diagnosis, genetic counseling, and patient stratification for clinical trials.
In the rarer cases of FSHD2 (OMIM#158901), more than 80% of subjects carry heterozygous
mutations in the SMCHD1 (structural maintenance of chromosomes flexible hinge domain containing
1) gene, which encodes a chromatin remodeling protein required for normal DNA methylation levels
and transcriptional repression at certain loci, including the inactive X chromosome, imprinted genomic
regions, and the D4Z4 arrays [44–46]. A few FSHD2 cases carry heterozygous mutations in the
DNMT3B (DNA methyltransferase 3 beta) gene [47] which is responsible for the establishment of the
proper de novo cytosine methylation profile during development. FSHD1 and, at a greater extent,
FSHD2 patients present D4Z4 DNA hypomethylation [33,48,49].
All these findings supported the hypothesis that significant alteration of the 4q35 epigenetic
landscape is central to FSHD, and that this occurs in FSHD1 by removal of a significant number of D4Z4
heterochromatic elements, and in FSHD2, via SMCHD1 or DNMT3B haploinsufficiency in presence of
a specific telomeric polymorphism, 4qA, which allows the expression of the most distal copy of the
DUX4 gene. More specifically, the PAS present on 4qA alleles allows for DUX4 mRNA polyadenylation,
stabilization, and translation [50–52]. In turn, all these alterations have brought forward a unifying
model for FSHD pathogenesis, involving the loss of epigenetic silencing and the consequent aberrant
expression of the DUX4 retrogene [52] (Figure 1). At present, these molecular characteristics are used
to explain FSHD pathogenesis and to develop therapeutic approaches.
3. The Debated Role of DNA Methylation in FSHD: Clinical and Families Studies
DNA methylation, a covalent post-synthetic modification of cytosines engaged in CpG
dinucleotides, is a heritable epigenetic mark. In healthy individuals, 70% to 90% of the CpGs
are methylated in somatic tissues, representing between 0.75% and 1% of the total number of bases in
the diploid human genome [53]. In human cells, dispersed CpGs are methylated whereas CpG clusters
(CpG islands) are mostly unmethylated [54]. Repetitive DNA sequences, enriched in CpGs, are usually
packed as condensed and repressed chromatin by dense methylation, a protective mechanism that
inhibits the invasion of the genome by the reactivation of transposable elements [55,56]. DNA
methylation plays important roles in a number of physiological processes, such as development [57,58]
and ageing [59–61]. Aberrant DNA methylation plays a causal role in a variety of diseases, including
cancer [62,63]. In general, cancer cells exhibit DNA hypermethylation of promoter regions of tumor
suppressor genes and global hypomethylation of repetitive DNA sequences accompanied with an
increased genomic instability or loss of heterozygosity. Methylation changes also contribute to a
number of diseases [64,65]. In particular, methylation have been investigated in diseases associated
with short tandem repeats DNA [66] and CpG methylation has been considered a possible disease
marker or modifier [67]. In fact, DNA hypermethylation is a critical feature of expanded short repeat
arrays, as reported for Fragile X syndrome [66] or Friedreich’s ataxia [68].
In FSHD, reduction of epigenetic silencing and aberrant gene expression seems to constitute the
underlying mechanism leading to disease. It has thus been thought that reduced methylation at the
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D4Z4 locus might represent a proxy indicator of the reduced transcriptional silencing associated with
FSHD. As a consequence, low CpG methylation of the D4Z4 sequence has been proposed as a reliable
marker in the FSHD diagnostic procedure [33,48,49].
To investigate this hypothesis on a large-scale, different works have been conducted on distinct
clinical cohorts. These studies assessed the methylation status at D4Z4, trying to correlate the percentage
of CpG methylation at the D4Z4 array with one or more FSHD features [69–73].
In early works, DNA methylation has been investigated by Southern blotting after digestion
with methylation-sensitive restriction enzymes (MSRE assay) [33,48] and hybridization with the
p13E11 probe, which detects a unique region upstream of the first repeat of the D4Z4 array (Figure 2).
The percentage of CpG methylation of the D4Z4 was estimated based on the density of the hybridization
signals of restriction fragments obtained prior or after restriction digestion with MSRE. The most
proximal FseI site within the D4Z4 array was considered as the most sensitive for this assay with an
estimated DNA methylation of 70–80% in healthy individuals and a significant decrease in FSHD1
patients. The MSRE assay possesses a restricted range of investigation since it evaluates only the few
CpGs detected by the various of MSREs without distinction between the D4Z4 repeat array on the 4q
and 10q chromosome [69], thus offering a narrow view of the D4Z4 methylation status.
To overcome these limitations, the bisulfite treatment of DNA followed by DNA sequencing (BSS)
has become the technique of choice to assess the D4Z4 methylation, virtually allowing the detection of
the methylation status of any CpGs within the array at once.
With this technical improvement, many works succeeded in reporting a more exhaustive analysis
of many CpGs within all D4Z4 units, even if without distinction between the 4q and 10q alleles [70,71].
Recently, Jones et al. [69] developed a 4q- and 10q-specific protocol for BSS analyses, which is
concomitantly able to capture the epigenetic status of the 3′ end of the most distal D4Z4 repeat and the
abutting A-type locus, which has been correlated with the pathogenic expression of DUX4 on short
D4Z4 arrays. A further advance in the methodology used in methylation studies was obtained by
Roche et al. [74] consisting in the assessment of DNA methylation at D4Z4 by using a custom deep
sequencing method after sodium bisulfite conversion of genomic DNA.
Nevertheless, the different attempts to use BSS analysis to assess D4Z4 epigenetic status suffer
from several limitations, both from a conceptual and a technical point of view.
As shown in Table 1, we compared the results of the main reports in the field. The comprehensive
analysis of these studies highlights some problematic points: (1) the lack of a clear description
of the clinical status of individuals within each cohort [69–72,74]; (2) the ambiguous definition of
asymptomatic or healthy carriers of a D4Z4 allele of reduced size, since they are included either in the
group of people with FSHD even if their clinical score is equal to zero, or in the control group despite
their liability to develop the disease [69,72]; (3) the constant attempt to correlate the methylation status
with the disease severity [70,72]; and (4) the effort to uniquely correlate hypomethylation at D4Z4 with
DUX4 expression [69,70,72].
From a technical point of view, the scenario is even more complicated by the fact that each
work used different primers sets in the BSS analyses to evaluate CpGs within different regions of
the D4Z4 array (Figure 2) and applied different statistical tools. First, for a proper analysis of DNA
methylation by bisulfite sequencing, (1) primers should not contain CpG sites within their sequence to
ensure unbiased amplification of both methylated and unmethylated DNA; and (2) primers should
be designed in a region containing enough number of non-CpG cytosines to avoid amplification of
incompletely modified genomic DNA [75]. Despite these recommendations in some of the works
considered here, the primer designed for BSS analysis included CpGs [69] or just one or few non-CpG
cytosines [73], which might affect the amplification of the converted DNA. Secondly, the selection of
different regions within the array led to controversial results about which is/are the region/s more
representative for the methylation status at D4Z4.
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Table 1. Systematic analysis and comparison of the major literature reports on D4Z4 methylation in FSHD.
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Figure 2. Overview of the D4Z4 repeats and of the region selected in methylation analyses. The D4Z4
array at 4q35 with an enlarged schematic representation of the D4Z4 distal most repeat (from position 1
to 3303 given relative to the two flanking KpnI sites). The different regions within D4Z4 are indicated:
LSau repe (position 1–340), Region A (position 869–1071), hhspm3 (position 1 13–1780), DUX4 ORF
(position 1792–3063), plus the ′ pLAM region. The figure highl hts the proximal BsaAI nd FseI
methylation-sensitive restriction sites analyzed by Southern blotting, and the location of bisulfite (BS)
PCR products used in the selected literature reports, each represented with a differently colored line.
The position of each region within the array, starting form the first KpnI site, is indicated together with
the assayed number of CpGs. The white lines within these regions indicate the presence of CpGs in
PCR primers.
As anticipated, we also observed that statistical analyses performed in each individual study
could not be compared with each other. For instance, in the work by Calandra et al. [72], the assessment
of the correlation between methylation levels and disease was performed focusing on a single CpG out
of ten within a region where D4Z4 hypomethylation is more evident.
In the study by Le mers et al. [70] the global methylation levels were estimated by eans of a novel
statistical model considering the D4Z4 rray s a linear string of mathematic units: the methylation
level was calculated as a linear function of D4Z4 rep ats number. In biological terms, this arbitrary
approach h s an intrinsic bias, since the repeat length of each allele affects the 3D chromatin structure of
the individual D4Z4 locus, and most likely its methylation status. Longer allel s generate a conde sed
chromatin structure and beyond a certain number of repetitive elements, the D4Z4 region displays a
high percentage of CpG methylation irrespective of the discrete D4Z4 repeat number of each individual
long allele.
Moreover, when considering alleles with fewer D4Z4 repeats, the effect on DNA methylation
differs in each D4Z4 allele and depends on the individual size. In fact, in families in which it was
possible to follow the segregation of D4Z4 alleles analyzed by bisulfite sequencing, it was possible to
discriminate between the two D4Z4 alleles carrying different repeat numbers. In these cases, the degree
of methylation roughly correlates with number of alleles with 10 or fewer repeats, but it was not
associated with the clinical condition [73].
Regardless of the methodologies used, data indicates that D4Z4 methylation is highly variable
also in healthy individuals and that hypomethylation concerns only a limited number of CpGs within
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the D4Z4 sequence. Hypomethylated CpGs are mostly clustered in the proximal part of the repeat but
not in the DUX4 promoter region per se or in the distal part of the coding sequence and 3′ UTR [69].
Overall, the observed hypomethylation of D4Z4 in FSHD patients shows a correlation with the
reduction of D4Z4 repeat units, even though the accurate review of the published data reveals a lack of
association between D4Z4 methylation level and FSHD1 clinical status.
In conclusion, a detailed phenotypic characterization should be recommended, together with
a common study design and a consensus approach in order to reach a more accurate and unbiased
evaluation of the global methylation pattern and to draw any conclusion on its clinical significance.
4. DNA Methylation in FSHD2
The SMCHD1 chromatin-associated factor has been implicated in FSHD on the basis of Whole
Exome Sequencing of 16 FSHD2 families presenting residual D4Z4 methylation below a threshold
of 25% at the most proximal FseI site [76]. It is now recognized that approximately 80% of FSHD2
patients are carriers of one SMCHD1 variant [77]. In a subsequent study, the threshold that defines
hypomethylation was estimated to be 30% of residual methylation at this proximal FseI site [70].
However, there seems to be no strict correlation between SMCHD1 variants, D4Z4 hypomethylation,
and the appearance of clinical signs. This is exemplified by the non-affected individuals who display
a low DNA methylation level <30%; 26% for Rf854-case 2398; 30% for Rf854-case 2434; and 29% for
Rf300-Cases 3 and 4, presented in the original work of Lemmers et al. [76]. More strikingly, considering
the clinical phenotype, the marked D4Z4 hypomethylation detected in the majority of FSHD2 patients
carrying a mutation in SMCHD1 is not accompanied either with a more severe phenotype or earlier
disease onset. Moreover, D4Z4 hypomethylation, in the presence of the haplotype 4qA/PAS distal
to the D4Z4 array, which is considered permissive of DUX4 expression, is not associated with a
muscle phenotype in patients with Bosma Arhinia and Microphthalmia syndrome (BAMS), patients
affected with ICF (Immunodeficiency, Centromeric Instability, and Facial anomalies) homozygotes
for DNMT3B mutation and their heterozygote parents [78], or patients carrying a deletion of the 18p
chromosome containing the SMCHD1 gene [79]. Besides, in the few families with FSHD index cases
carrying a mutation in DNMT3B [47] or an 18p deletion [80], the presence of a DNA mutation and D4Z4
hypomethylation does not segregate with clinical signs of the disease. Furthermore, as highlighted by
molecular combing [81], a significant proportion of individuals affected by FSHD display an atypical
genotype, with complex distal rearrangements [82], presence of proximal deletions, additional 10q
alleles, in the absence of D4Z4 array shortening, SMCHD1 variants, or D4Z4 hypomethylation [83].
So far, further investigations are required to answer a few important questions, such as the role of
epigenetic alterations in FSHD, whether hypomethylation leads to DUX4 activation and, above all,
how this translates into a specific muscle phenotype.
5. Changes in DNA Methylation at D4Z4 Upon Reprogramming
Pluripotent stem cells represent an important tool to model human genetic disorders, as they
can be used to analyze the effect of specific genomic alterations in early development or during
differentiation [83–86]. Cell reprogramming always involves profound epigenetic changes and the
acquisition of an epigenetic pattern similar to that of pluripotent embryonic stem cells. The pattern of
DNA methylation is not fully erased after reprogramming. Hence, reprogrammed cells keep memory
of the pattern of the parental somatic cells they were derived from, but also acquire DNA methylation
profiles specific of induced pluripotent stem cells (iPSCs). iPSCs obtained by reprogramming of
patients’ cells have been recently used to clarify the molecular basis of several “epigenetic” diseases.
For instance, in human hiPSCs from Fragile X (FXS) patients, the FMR1 promoter region aside the
5′UTR with expanded CGG triplets (n > 200) remains in most cases hypermethylated, suggesting that
once established in FXS fibroblasts, these epigenetic marks are stably maintained after reprogramming,
whereas in other cases, the methylation pattern of the disease-associated locus does not reflect the
profile of the donor cells [87–90].
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Concerning FSHD1, the investigation of DNA methylation at D4Z4 in iPSCs from affected subjects
and healthy donors revealed that these cells do not retain the methylation pattern inherited from the
donor cells, but acquire a new methylation profile. This argues for the presence of two mechanisms
acting at D4Z4 upon reprogramming: an active “erasure” of the cell-of-origin epigenetic profile and
a “rewriting” of a de novo methylation pattern at the array. Moreover, reports demonstrate that the
D4Z4 methylation was identical from clone to clone from both FSHD1 patients and controls, indicating
that remethylation of D4Z4 upon epigenetic reprogramming does not depend on the residual number
of D4Z4 repeats [79].
More in details, the comparison of the methylation profile between FSHD iPSCs and human
Embryonic Stem Cells (hESCs) with a short or long D4Z4 array, revealed a trend toward a high
methylation level, without any significant difference between FSHD1 and control cells and between
iPSCs and ESCs.
The higher methylation level found at D4Z4 in pluripotent cells further suggests that D4Z4
methylation status does not correlate with the number of repeats but is a feature of stemness, which
highlights once more the complex but yet unknown regulatory mechanisms of this locus [79].
Interestingly, recent findings revealed a key role for DUX4 at very early stages of human
development and the activation of embryonic genes at the zygotic genome activation stage
(ZGA) [91–94], a stage characterized by profound methylation changes. A high level of methylation
was observed in hiPSCs and hESCs. These cells represent a later developmental stage compared to ZGA
since they are derived from the blastocyst inner cell mass (ICM), a developmental stage characterized by
remethylation of the zygotic genome after post-fertilization waves of demethylation up to the morula
stage. These findings rule out the connection between DUX4 expression and D4Z4 hypomethylation.
Additional features, such as the size of the abutting telomere, might be also implicated in the
regulation of D4Z4 methylation. Interestingly, the highest level of methylation is observed in cells
where telomerase is reactivated, such as hiPSCs and ES cells [95–97]. These observations suggest the
possible link between D4Z4 methylation and telomeres and also draw attention to the complexity of
the epigenetic regulation of this macrosatellite element during development.
6. Trans-Acting Factors
The possibility to use the percentage values of methylated CpGs at D4Z4 as a diagnostic marker for
FSHD is further weakened by the fact that DNA methylation could not be considered per se. It is now
well established that DNA methylation is only one among numerous indicators of chromatin structure
at D4Z4 and several research groups reported that alterations of chromatin structure is reflected by
post-translational histone modifications [48,98–100], by the binding of various non-histone proteins and
RNAs on the repeat array [39,43,101], and by higher order chromatin structures formation [102–104].
Epigenetic alteration of chromatin relies on DNA methylation and on histone tails modifications
in nucleosomes, which together determine the so called “epigenetic signature” of a specific region.
It has been reported that the D4Z4 array contains histone H3 Lysine 9 trimethylation (H3K9me3),
a repressive mark associated with heterochromatin formation, together with H3K27me3, a repressive
chromatin mark associated with Polycomb silencing [33,43,98]. A specific loss of H3K9me3 followed by
the loss of HP1γ and cohesin binding at D4Z4, suggestive of a more relaxed chromatin structure [98],
was reported both for FSHD1, in the presence of a reduced number of repeats, and also in FSHD2
subjects. The loss of repressive histone marks is not a direct consequence of DNA hypomethylation
since H3K9me3 enrichment at D4Z4 was unaltered in ICF syndrome, which displays severe DNA
hypomethylation at the 4q35 locus [49,98]. Besides, H3K27 presence at D4Z4 did not show any changes
between the control and FSHD muscle cells [43,102].
Other observations argue for a role for the Polycomb proteins in the epigenetic regulation at D4Z4:
The methyl-transferase EZH2 (Enhancer of zeste homolog 2), a component of Polycomb repressive
complex 2 (PRC2), was shown to be reduced in FSHD muscle cells, while ASH1L (ASH1 Like Histone
Lysine Methyltransferase), a member of the Trithorax complex associated with transcriptionally
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active chromatin, was found to be specifically recruited to D4Z4 in FSHD cells [43]. Notably, ASH1L
recruitment has been shown to be dependent on the expression of the non-coding RNA DBE-T,
transcribed by to the most proximal D4Z4 unit. In particular, DBE-T-mediated ASH1L recruitment to
D4Z4 in FSHD cells is reported to mediate histone H3 lysine 36 dimethylation (H3K36me2), a major
histone mark associated with transcriptional activation, leading to chromatin remodeling and 4q35
gene transcription [43].
Among transcription factors, two proteins have mainly been associated with D4Z4, YY1 Yin
Yang 1) and CTCF (CCCTC-binding factor). Reports demonstrated the association of a repressor
protein complex, named DRC (D4Z4 Recognition Complex) composed of YY1, a known transcriptional
repressor, HMGB2 (high-mobility group protein 2), an architectural protein, and nucleolin, with the
27 bp DBE (D4Z4 binding element) sequence contained within each D4Z4 [39]. YY1 was reported to be
the major factor bound to the DBE, although other DRC components contributed to DNA binding
affinity and specificity. It is noteworthy that YY1 binds DNA only when it is not methylated [105].
The region encompassing the DBE element is hypermethylated in FSHD and control subjects, except
from the CpGs neighboring the YY1 consensus site, which show variable levels of methylation (Tupler,
personal observation and [106]). Conversely, CTCF binding is disrupted by CpG methylation [107].
Two CTCF binding sites are located within the 5′ region of D4Z4 repeat, which is reported to display
hypomethylation in the presence of a DRA [74,101,106,108]. CTCF binding to 4q35 displays an
inverse correlation to D4Z4 copy number and function as a Lamin A/C-dependent chromatin insulator,
protecting D4Z4 from epigenetic silencing by surrounding heterochromatic regions, therefore keeping
the D4Z4 chromatin open primarily in a DRA context [102]. Since CTCF has also been shown to
mediate chromatin loop formation and to generate TADs (topologically associated domain) [108–111]
the increased CTCF binding to D4Z4 in FSHD may result in altered nuclear and chromatin organization.
In particular, using an integrated genome wide approach (4C-seq) it has been reported that 4q-D4Z4
interactome is altered in FSHD1, leading to a chromatin switch toward an active state (mediated
by enhancer–promoter interactions), which in turn results in the transcriptional activation of genes
involved in muscular atrophy [103].
All these observations further complicate the comprehension of D4Z4 activity regulation and
confirm that DNA methylation and its consequence on DUX4 activation are only a part of the fine
tuning controlling the transition between healthy and disease status.
7. The Significance of D4Z4 Hypomethylation in FSHD and Its Implication for
Clinical Counseling
The main current theory about the FSHD pathogenic model involves the aberrant expression of
DUX4 retrogene caused by epigenetic changes in the D4Z4 region [93]. This should be due to reduced
methylation, either for D4Z4 repeats reduction in FSHD1 or for the effect of the SMCHD1 gene in
FSHD2 [52,76]. However, the literature reports clearly reveals that hypomethylation correlates with
the reduction of the arrayed repeats, but not with the disease status [69–72]. It is thus conceivable that
in FSHD1, hypomethylation is a consequence of the chromatin structure present in the contracted
allele, instead of an indicator of its function.
This also holds true for FSHD2, especially for patients who carry mutations in SMCHD1, deletions
of the 18p locus or mutations in DNMT3B, and especially considering the molecular overlaps (D4Z4
hypomethylation) with other unrelated diseases, such as BAMS, ICF, or 18p deletion syndromes
(Figure 3).
All these observations indicate that accurate diagnosis should not completely rely on molecular
findings. Large studies based on clinical evaluation demonstrate that (1) 2% of healthy individuals from
the general population bear one FSHD1-sized D4Z4 allele with the possibility of expressing the DUX4
transcript [27]; (2) the clinical severity of FSHD does not clearly associate with the size of the deletion of
the D4Z4 allele [7,12,112]; (3) the penetrance of FSHD is not complete, with 20–50% of relatives carrying
FSHD1-sized D4Z4 alleles being healthy [7,9,10,25,34,35]; (4) the disease penetrance decreases among
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second-fifth degree relatives in FSHD families [7]; (5) there are families showing affected subjects in
one generation, families with a single affected subject, and also subjects with atypical phenotypes in
which additional mutations in genes causing other neuromuscular diseases have been found [7,30,34];
in addition, independent studies showed that (6) SMCHD1 mutations cause the Bosma developmental
syndrome (OMIM #603457) and D4Z4 hypomethylation has been found in these patients with no
documented signs of FSHD [113,114]; (7) SMCHD1 mutations have been found in subjects with Limb
Girdle Muscular Dystrophies (LGMDs) (Tupler, unpublished NGS data); (8) homozygous or compound
heterozygous mutations in DNMT3B cause immunodeficiency-centromeric instability-facial anomalies
syndrome-1 (ICF1) (OMIM #242860), a syndrome characterized by hypo- or agammaglobulinemia
and frequent infections that determine poor life expectancy; and (9) some ICF1 cases showed D4Z4
hypomethylation with no signs of FSHD [78] (Figure 3).
Thus, SMCHD1 and DNMT3B mutations have been associated with congenital diseases, whereas
FSHD is an adult progressive disease with no congenital presentation, and very importantly, no
FSHD patients carrying SMCHD1 mutations have signs of Bosma syndrome even when they carry
overlapping missense mutations or mutations in the same regions of the coding sequence. These
data are consistent with the frequent observation that genes play roles in multiple pathways, and
that different mutations within the same gene can contribute to distinct phenotypes with different
mechanisms of action (Figure 3).
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Figure 3. The lack of a unique molecular signature in FSHD complicates genotype–phenotype
correlation in clinical practice. The figure illustrates the complex molecular scenario observed in
individuals with clinical features of FSHD. Hypomethylation is observed in a large subset of them,
including in patients who carry a mutation in SMCHD1 or DNMT3B. This scheme also highlights that
hypomethylation of D4Z4 is observed in other rare diseases linked to mutations in SMCHD1 (BAMS),
DNMT3B (ICF) or carrying a deletion of the 18p locus that contains the SMCHD1 gene.
8. Conclusions
Unraveling the mechanism leading to FSHD reveals to be a prickly issue. One of the major
challenges we face in clinical practice is that there is no unique molecular sign ture discrimi ating
FSHD patients. We are still trying to promote a inear c mmo diagnostic approach to FSHD, an
ambitious objective that should involve all clinical practitioners in the field, as displayed by the use of
the FSHD Comprehensive Clinical Evaluation Form [29,115]. At present, current available molecular
markers are not sufficient for a proper diagnosis or prognosis, nor for genetic counseling, but patients
are still looking for support and assistance on a daily basis. Because of the large phenotypic variations
observed among affected subjects, the clinical assessment should be performed carefully considering
the family context, with the attempt to find a pattern of inheritance and shared features
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Our hypothesis is that FSHD clinical variability may result from the combinatorial effects of
variant alleles in genes exerting a detrimental effect on muscle function, together with epigenetic
changes influencing their expression. The genetic background of each individual, including harmful
gene variants or variants in regulatory elements, might have a crucial role in disease penetrance,
high clinical variability and unpredictable progression. In view of the results of genotype–phenotype
studies on FSHD cohorts and of the recent findings on the effects of SMCHD1 mutations, it is advisable
to apply a stringent analysis of clinical phenotypes to decipher molecular data. An oversimplification
may cause misdiagnosis and biased interpretation of molecular findings with severe effects not only
for research, following incorrect hints, but also for clinical practice. The systematic collection of precise
phenotypic data of patients and families should become an ineludible tool to support research in
human molecular genetics and to translate molecular findings into clinical practice.
Besides, the D4Z4 array and the regulation of its chromatin dynamics has become more and more
intriguing over the recent years because of the identification of numerous factors able to regulate its
chromatin state and topology within the genome. This element has often been considered separately
and not necessarily in the context of the 4q35 locus itself, which also contains several microsatellites
of unknown function upstream of D4Z4, and repetitive beta satellite elements distal to the D4Z4, not
mentioning the nearby telomere. Variations in macrosatellite number and associated features suggest that
not only D4Z4, but also other elements of the large family of repetitive sequences, might play important
regulatory functions either locally or at long distances on gene expression. It is speculated that copy
number variations of repetitive elements might be associated with variations in human phenotype and
they could explain different susceptibility to the disease and missing heritability. In FSHD, the molecular
features of the 4q35 sub-telomeric region could be an example of this molecular and clinical variegation.
In conclusion, the study of CpG methylation, performed by several groups and in distinct ways,
failed to reveal a clear and unifying theory about the “epigenetic” basis of FSHD. Indeed, the D4Z4
methylation status does not mirror the clinical expression of the disease. The measurement of this
epigenetic mark must be interpreted with caution and may support the characterization of individual
FSHD families in clinical practice rather than be assumed as a marker of D4Z4 function in FSHD.
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